+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multi-institutional phase II, randomized dose finding study of defibrotide in patients with severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Promising response rate without significant toxicity in a high risk population



Multi-institutional phase II, randomized dose finding study of defibrotide in patients with severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Promising response rate without significant toxicity in a high risk population



Blood 98(11 Part 1): 853a, November 16



Introduction: DF, a single stranded polydeoxyribonucleotide, is an adenosine receptor agonist which has aptameric activity on endothelium with anti-thrombotic, anti-ischemic and thrombolytic properties, especially on microvasculature, but does not produce significant systemic anti-coagulant effects. Studies have suggested that DF improved survival in pts with severe VOD and MOF with minimal toxicity. Most responses have been recorded between 20-40mg kg/d in intra-pt dose escalation trials but a uniformly effective dose has not been defined. Methods: A phase II randomized study is being carried out in pts with severe VOD and MOF to determine the effective dose. The primary endpoint is to define the complete response (CR) rate of pts with severe VOD treated with DF at either a dose of 25mg/kg/d (arm A) or 40 mg/kg/d (arm B). Secondary endpoints include any attributable toxicity; correlation of response with outcome and PAI-1 levels in pts treated with DF, and whether either dose shows a trend toward decreased mortality at day (d) +100 post SCT. The clinical diagnosis of VOD is defined by Baltimore criteria and severity determined by gtoreq30% risk on the Bearman model and/or the presence of MOF. Abdominal US with doppler is required prior to enrollment with liver biopsy and wedged hepatic venous pressure gradient measurement, necessary in confounding cases. Pts with gtoreq grade II GVHD are excluded and pts must be hemodynamically stable. Pts treated with prior tPA are ineligible. Pts are centrally registered and randomized with subsequent third party chart review. Treatment arms are stratified for age (<18y) and cyclophosphamide (Cy)- based conditioning. Treatment should continue gtoreq14d. Pts receiving <3d of therapy are inevaluable for response. CR is defined as a bilirubin <2 mg/dl with resolution of VOD-related MOF. Samples for special lab studies including PAI-1 are drawn prior to therapy and every 3d until completion of treatment. Results: 24 of the required 30 evaluable pts have been enrolled to date. 1 pt was found ineligible on liver biopsy and did not start therapy. 14 pts have been randomized to arm A and 9 pts to arm B with 23 pts treated and 20 pts currently evaluable for response. 20 pts underwent allo- and 3 auto- SCT, with 4 undergoing gtoreq2nd SCT. Median age was 22y (8mos-56y). Conditioning included CY in 20 pts (87%), busulfan in 6 (26%) and TBI in 14 (61%). At DF initiation (median d+14, range 6-30), median bilirubin was 8.4 mg/dl (range 2-21.1) and median weight gain of 15.9% (range 2.7-36.6%). Ascites was present in 21/23 (91%); RUQ pain in 16/23 (73%); hepatomegaly in 17/23 (74%), and abnormal portal flow in 13/23 (57%). MOF was present in 22/23 (96%), with 2 pts intubated. The median duration of DF therapy was 18d (2-41). No significant attributable DF toxicity has been reported. CR was observed in 9/20 pts (45%; 95% CI (23.1%, 68.5%)) with survival to d+100 in 8/20 (40%; 95% CI (19.1%, 64%)). Analysis of PAI-1 and a comparison between the two doses will be completed upon enrollment of the entire study cohort. Conclusion: The promising response rate, long term survival and favorable tolerability profile in this first prospective, randomized trial of DF in pts with severe VOD and MOF confirm the encouraging results of prior single arm, emergency use studies. Moreover, the use of rigorous selection criteria and central review has minimized the confounding effects of investigator variability in the diagnosis and assessment of acuity in this multi-institutional study of DF in severe VOD.

(PDF emailed within 1 workday: $29.90)

Accession: 035349254

Download citation: RISBibTeXText


Related references

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100(13): 4337-4343, 2002

Defibrotide Appears Effective and Safe in a Phase II, Randomized Study of Patients with Severe Veno-Occlusive Disease and Multi-System Organ Failure Post Stem Cell Transplantation. Blood 100(11): Abstract No 414, November 16, 2002

Defibrotide is effective in the treatment of severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Results of a phase II, multicenter, randomized Study. Blood 102(11): 193a, November 16, 2003

Multi-institutional emergency use of defibrotide in 75 pts post SCT with severe VOD and multi-system organ failure Response without significant toxicity in a high risk population. Blood 96(11 Part 1): 585a, November 16, 2000

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biology of Blood and Marrow Transplantation 16(7): 1005-1017, 2011

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92(3): 737-744, 1998

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127(13): 1656-1665, 2016

The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. Journal of Medical Economics 20(5): 453-463, 2016

Treatment of severe veno-occlusive disease with defibrotide Compassionate use results in efficacy without significant toxicity in a high risk population. Blood 90(10 SUPPL 1 PART 1): 252A, Nov 15, 1997

Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 22(3): S188-S189, 2016

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation. Hematology/Oncology and Stem Cell Therapy 11(1): 47-51, 2017

Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. Biology of Blood and Marrow Transplantation 22(3): S25-S26, 2016

Post Hoc Analysis of Defibrotide for Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation in Subgroups of Patients with and Without Leukemia. Biology of Blood and Marrow Transplantation 23(3): S296-S297, 2017

Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation. Clinical Drug Investigation 34(12): 895-904, 2015

Pre-emptive therapy with defibrotide to prevent severe veno-occlusive disease after stem cell transplantation. Blood 102(11): 466a, November 16, 2003